Document Preview Unavailable
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)
Marwân-Al-Qays Bousmah; Nishimwe, Marie; Tovar-Sanchez, Tamara; Wandji, Martial Lantche; Mpoudi-Etame, Mireille; et al. IDEAS Working Paper Series from RePEc, 2021.You might have access to this document
-
Try and log in through your institution to see if they have access to the full text.
Log in through your library




